Former Chief Operating Officer · Zentalis Pharmaceuticals, Inc. (ZNTL)

Iris Roth

FY2023 is the first fiscal year CompBrief holds for Iris Roth as a named executive officer of Zentalis Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$5,931,787

Salary $287,423Stock awards $990,675

3rd of 6 named executive officers at Zentalis Pharmaceuticals by FY2023 total.

6 named officers on file for Zentalis Pharmaceuticals, FY2023

Iris Roth’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • ZNTL’s disclosed peer group of 23 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Zentalis Pharmaceuticals’s whole pay program stands against its peers

  • Zentalis Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ZNTL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2024 (DEF 14A).

Free

Get Iris Roth’s full pay file as a PDF — free

More than this page: up to 10 years of Iris’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Iris Roth compensation by year

Zentalis Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Zentalis Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$287,423
Bonus$0
Stock awards$990,675
Option awards$4,033,249
Non-equity incentive$173,790
Pension and deferred compensation$0
All other$446,650
Total$5,931,787

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Zentalis Pharmaceuticals, Inc. DEF 14A filed April 29, 2024, accession 0001725160-24-000096, and prior-year filings.

How this page was built: the Zentalis Pharmaceuticals, Inc. filed document, accession 0001725160-24-000096. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.

Zentalis Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Kimberly BlackwellChief Executive Officer$12,853,590
Cam GallagherFormer President, Interim Chief Financial Officer and Interim Treasurer$8,581,060
Iris Roth · this pageFormer Chief Operating Officer$5,931,787
Melissa EpperlyFormer Chief Financial Officer and Treasurer$5,631,323
Kevin BunkerFormer Chief Scientific Officer$5,115,956
Andrea PaulChief Legal Officer and Corporate Secretary$2,629,027

The full Zentalis Pharmaceuticals compensation record

free company brief

This page is one person within Zentalis Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Zentalis Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Zentalis Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Iris Roth's compensation dossier · One-time report. No refunds.